Lundbeck's Ovation

With the patent expiry of its lead products looming for H. Lundbeck A/S, the Danish pharma's acquisition of Ovation Pharmaceuticals Inc. is more about top-line growth than establishing a U.S. bridgehead. While it is true that the acquisition would fulfill Lundbeck's ambition to build a presence in the U.S., the main drivers of the potential $900 million purchase are Sabril vigabatrin and Xenazine tetrabenzine.

"Ovation's pipeline is a great match for our own, and combining the two gives us a lot of opportunities for potential launches of new medicines in the coming years," Lundbeck President and CEO Ulf Wiinberg told BioCentury. "On top of that, we have for some time now been looking for commercial infrastructure in the U.S. and so are happy that we have found one that is up and running, profitable and growing."...